Secukinumab (AIN-457) for the treatment of Psoriasis

References

• Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin. 1996;14(3):485–496.
   PubMed Web of Science ®Google Scholar
• Boehncke W-H, Schön MP. Psoriasis. Lancet. 2015;386:983–994. DOI:10.1016/S0140-6736(14)61909-7.
   PubMed Web of Science ®Google Scholar
• Novelli L, Chimenti MS, Chiricozzi A, et al. The new era for the treatment of psoriasis and psoriatic arthritis: perspectives and validated strategies. Autoimmun Rev. 2014;13(1):64–69.
   PubMed Web of Science ®Google Scholar
• Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73(1):37–49.
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis: results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338.
   PubMed Web of Science ®Google Scholar
• D’Souza LS, Payette MJ. Estimated cost efficacy of systemic treatments that are approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis. J Am Acad Dermatol. 2015;72(4):589–598.
   PubMed Web of Science ®Google Scholar
• Heydendael VMR, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med. 2003;349(7):658–665.
   PubMed Web of Science ®Google Scholar
• Saurat J-H, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158(3):558–566.
   PubMed Web of Science ®Google Scholar
• Barker J, Hoffmann M, Wozel G, et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol. 2011;165(5):1109–1117.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51(4):534–542.
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366(9494):1367–1374.
   PubMed Web of Science ®Google Scholar
• Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56(1):31.e1–15.
   PubMed Web of Science ®Google Scholar
• Torii H, Nakagawa H, Japanese Infliximab Study investigators. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci. 2010;59(1):40–49.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52(10):3279–3289.
   PubMed Web of Science ®Google Scholar
• Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106–115.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55(4):598–606.
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349(21):2014–2022.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139(12):1627–1632. discussion 1632.
   PubMed Web of Science ®Google Scholar
• Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152(6):1304–1312.
   PubMed Web of Science ®Google Scholar
• Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006;367(9504):29–35.
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362(2):118–128.
   PubMed Web of Science ®Google Scholar
• Kragballe K, Jansén CT, Geiger JM, et al. A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study. Acta Derm Venereol. 1989;69(1):35–40.
   PubMed Web of Science ®Google Scholar
• Murray HE, Anhalt AW, Lessard R, et al. A 12-month treatment of severe psoriasis with acitretin: results of a Canadian open multicenter study. J Am Acad Dermatol. 1991;24(4):598–602.
   PubMed Web of Science ®Google Scholar
• Schmitt J, Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology. 2005;210(3):194–199.
   PubMed Web of Science ®Google Scholar
• Langley RGB, Feldman SR, Nyirady J, et al. The 5-point Investigator’s Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat. 2015;26(1):23–31.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Swensen AR, Nyirady J, et al. The psoriasis symptom diary: development and content validity of a novel patient-reported outcome instrument. Int J Dermatol. 2014;53(6):714–722.
   PubMed Web of Science ®Google Scholar
• Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6(11):1123–1132.
   PubMed Web of Science ®Google Scholar
• Dong C. Targeting Th17 cells in immune diseases. Cell Res. 2014;24(8):901–903.
   PubMed Web of Science ®Google Scholar
• Isailovic N, Daigo K, Mantovani A, et al. Interleukin-17 and innate immunity in infections and chronic inflammation. J Autoimmun. 2015;60:1–11.
   PubMed Web of Science ®Google Scholar
• Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol. 2010;10(7):479–489.
   PubMed Web of Science ®Google Scholar
• Leipe J, Grunke M, Dechant C, et al. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum. 2010;62(10):2876–2885.
   PubMed Web of Science ®Google Scholar
• Marder W, Khalatbari S, Myles JD, et al. Interleukin 17 as a novel predictor of vascular function in rheumatoid arthritis. Ann Rheum Dis. 2011;70(9):1550–1555.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Durez P, Richards HB, et al. One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study. J Rheumatol. 2014;41(3):414–421.
   PubMed Web of Science ®Google Scholar
• Yeremenko N, Paramarta JE, Baeten D. The interleukin-23/interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis. Curr Opin Rheumatol. 2014;26(4):361–370.
   PubMed Web of Science ®Google Scholar
• Zeng L, Lindstrom MJ, Smith JA. Ankylosing spondylitis macrophage production of higher levels of interleukin-23 in response to lipopolysaccharide without induction of a significant unfolded protein response. Arthritis Rheum. 2011;63(12):3807–3817.
   PubMed Web of Science ®Google Scholar
• Burton PR, Clayton DG, Cardon LR, et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet. 2007;39(11):1329–1337.
   PubMed Web of Science ®Google Scholar
• Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693–1700.
   PubMed Web of Science ®Google Scholar
• Targan SR, Feagan BG, Vermeire S, et al. Mo2083 a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and efficacy of AMG 827 in subjects with moderate to severe Crohn’s disease. Gastroenterology. 2012;143(3):e26.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318–1328.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sendid B, Jouault T, et al. Secukinumab failure in Crohn’s disease: the yeast connection? Gut. 2013;62(5):800–801.
   PubMed Web of Science ®Google Scholar
• Tzartos JS, Friese MA, Craner MJ, et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol. 2008;172(1):146–155.
   PubMed Web of Science ®Google Scholar
• Elain G, Jeanneau K, Rutkowska A, et al. The selective anti-IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A-induced levels of IL6 in human astrocytes. Glia. 2014;62(5):725–735.
   PubMed Web of Science ®Google Scholar
• Deiß A, Brecht I, Haarmann A, et al. Treating multiple sclerosis with monoclonal antibodies: a 2013 update. Expert Rev Neurother. 2013;13(3):313–335.
   PubMed Web of Science ®Google Scholar
• Fernández Ó, Arnal-García C, Arroyo-González R, et al. Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (III). Rev Neurol. 2013;57(7):317–329.
   PubMed Web of Science ®Google Scholar
• Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73:400–409. DOI:10.1016/j.jaad.2015.05.013.
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Leonardi CL, Girolomoni G, et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol. 2015;73(1):27–36.e1.
   PubMed Web of Science ®Google Scholar
• Paul C, Lacour J-P, Tedremets L, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015;29(6):1082–1090.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Prinz JC, Gottlieb AB, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172(2):484–493.
   PubMed Web of Science ®Google Scholar
• Frleta M, Siebert S, McInnes IB. The interleukin-17 pathway in psoriasis and psoriatic arthritis: disease pathogenesis and possibilities of treatment. Curr Rheumatol Rep. 2014;16(4):414.
   PubMed Web of Science ®Google Scholar
• Sutton CE, Mielke LA, Mills KHG. IL-17-producing γδ T cells and innate lymphoid cells. Eur J Immunol. 2012;42(9):2221–2231.
   PubMed Web of Science ®Google Scholar
• van den Berg WB, McInnes IB. Th17 cells and IL-17a: focus on immunopathogenesis and immunotherapeutics. Semin Arthritis Rheum. 2013;43(2):158–170.
   PubMed Web of Science ®Google Scholar
• Koenders MI, Marijnissen RJ, Joosten LAB, et al. T cell lessons from the rheumatoid arthritis synovium SCID mouse model: CD3-rich synovium lacks response to CTLA-4Ig but is successfully treated by interleukin-17 neutralization. Arthritis Rheum. 2012;64(6):1762–1770.
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibodies to watch in 2015. MAbs. 2015;7(1):1–8.
   PubMed Web of Science ®Google Scholar
• Chioato A, Noseda E, Stevens M, et al. Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center study. Number. 2012;19. DOI:10.1128/CVI.00386-12.
   Web of Science ®Google Scholar
• Chiricozzi A, Krueger JG. IL-17 targeted therapies for psoriasis. Expert Opin Investig Drugs. 2013;22(8):993–1005.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Guttman-Yassky E, Suárez-Fariñas M, et al. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol. 2011;131(3):677–687.
   PubMed Web of Science ®Google Scholar
• Gooderham M, Posso-De Los Rios CJ, Rubio-Gomez GA, et al. Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review. Skin Therapy Lett. 2015;20(1):1–5.
   Google Scholar
• Reich K, Papp KA, Matheson RT, et al. Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis. Exp Dermatol. 2015;24(7):529–535.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Sieper J, Braun J, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis. 2014;73(2):349–356.
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals Corporation. Advisory Committee briefing book: secukinumab (AIN457) [Internet]. 2014. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DermatologicandOphthalmicDrugsAdvisoryCommittee/UCM419023.pdf
   Google Scholar
• Wang J., Wang Y-M. Food and drug administration Center for Drug Evaluation and Research: Clinical pharmacology and biopharmaceutics review [Internet]. Application number: 125504Orig1s000. 2013. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125504Orig1s000ClinPharmR.pdf
   Google Scholar
• Novartis Pharmaceuticals Corporation. Secukinumab (AIN457) BLA 125,504 [Internet]. Presented at the Dermatologic and ophthalmic drugs advisory committee meeting; 2014 Oct 20; Silver Spring (MD). Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DermatologicandOphthalmicDrugsAdvisoryCommittee/UCM420462.pdf
   Google Scholar
• Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2(52):52ra72.
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013;168(2):412–421.
   PubMed Web of Science ®Google Scholar
• Rich P, Sigurgeirsson B, Thaci D, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2013;168(2):402–411.
   PubMed Web of Science ®Google Scholar
• Xiong H-Z, Gu J-Y, He Z-G, et al. Efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2015;8(3):3156–3172.
   PubMed Web of Science ®Google Scholar
• Thaçi D, Humeniuk J, Frambach Y, et al. Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). Br J Dermatol. 2015;173:777–787. DOI:10.1111/bjd.13814.
   PubMed Web of Science ®Google Scholar
• Strober BE, Nyirady J, Mallya UG, et al. Item-level psychometric properties for a new patient-reported psoriasis symptom diary. Value Health. 2013;16(6):1014–1022.
   PubMed Web of Science ®Google Scholar
• Paul C, Reich K, Gottlieb AB, et al. Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial. J Eur Acad Dermatol Venereol. 2014;28(12):1670–1675.
   PubMed Web of Science ®Google Scholar
• Reich K, Sullivan J, Arenberger P, et al. Secukinumab is effective in subjects with moderate to severe plaque psoriasis with significant nail involvement: 16 weeks results from the TRANSFIGURE study. In: 23rd world congress of dermatology abstracts and proceedings; 2015 Jun 11; Vancouver.
   Google Scholar
• McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386:1137–1146.
   PubMed Web of Science ®Google Scholar
• Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329–1339.
   PubMed Web of Science ®Google Scholar
• Mease P, McInnes IB, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, improves active psoriatic arthritis and inhibits radiographic progression: efficacy and safety data from a phase 3 randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum. 2014;66:S423–S424.
   Google Scholar
• Baraliakos X, Braun J, Sieper J, et al. THU0233 secukinumab reduces sacroiliac joint and spinal inflammation in patients with ankylosing spondylitis: MRI data from a phase 3 randomized, double-blind, placebo-controlled study (MEASURE 1). Ann Rheum Dis. 2015;74:281.
   Google Scholar
• Sieper J, Braun J, Baraliakos X, et al. Secukinumab efficacy in anti-Tnf-naive patients and patients previously exposed to anti-Tnf therapy: results of a randomized, double-blind, placebo-controlled phase 3 study (Measure 2) in active ankylosing spondylitis. Ann Rheum Dis. 2015;74(Suppl 2):272–272.
   Google Scholar
• Craddock J, Markovic-Plese S. Immunomodulatory therapies for relapsing-remitting multiple sclerosis: monoclonal antibodies, currently approved and in testing. Expert Rev Clin Pharmacol. 2015;8(3):283–296.
   PubMed Web of Science ®Google Scholar
• Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013;120(4):777–787.
   PubMed Web of Science ®Google Scholar
• Ward N, Guettner A, Sands B. Secukinumab safety and tolerability in subjects with moderate to severe plaque psoriasis: a pooled subgroup analysis of 10 clinical studies evaluating exacerbation of Crohn’s disease [abstract no. P8233]. J Am Acad Dermatol. 2014;70(5 Suppl 1):AB188.
   Web of Science ®Google Scholar
• Ohtsuki M, Morita A, Abe M, et al. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study. J Dermatol. 2014;41(12):1039–1046.
   PubMed Web of Science ®Google Scholar
• Tsai T, Blauvelt A, Karpov A, et al. Evaluation of infections with secukinumab in a pooled analysis of 10 clinical studies of moderate-to-severe plaque psoriasis. J Invest Dermatol. 2014;134:S33–S33.
   Google Scholar
• Griffiths CE, Prinz J, Güttner A, et al. Behavior of neutrophil count during 52 weeks of treatment with secukinumab: an analysis of pooled data from the phase 2 and phase 3 clinical study programs for secukinumab in moderate-to-severe plaque psoriasis [abstract no 8266]. Presented at the 72nd annual meeting of the American academy of dermatology; 2014 Mar 21–25; Denver (CO).
   Google Scholar
• Madhur MS, Funt SA, Li L, et al. Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol. 2011;31(7):1565–1572.
   PubMed Web of Science ®Google Scholar
• Danzaki K, Matsui Y, Ikesue M, et al. Interleukin-17A deficiency accelerates unstable atherosclerotic plaque formation in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2012;32(2):273–280.
   PubMed Web of Science ®Google Scholar
• Simon T, Taleb S, Danchin N, et al. Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction. Eur Heart J. 2013;34(8):570–577.
   PubMed Web of Science ®Google Scholar
• Boehncke W-H, Menter A. Burden of disease: psoriasis and psoriatic arthritis. Am J Clin Dermatol. 2013;14(5):377–388.
   PubMed Web of Science ®Google Scholar
• Van De Kerkhof P, Strober B, Karpov A, et al. Evaluation of malignancy risk with secukinumab treatment in a pooled analysis of 10 clinical studies of moderate-to-severe plaque psoriasis up to 52 Weeks. J Invest Dermatol. 2014:S33–S33.
   Google Scholar
• He D, Li H, Yusuf N, et al. IL-17 mediated inflammation promotes tumor growth and progression in the skin. PLoS One. 2012;7(2):e32126.
   PubMed Web of Science ®Google Scholar
• Sanford M, McKeage K. Secukinumab: first global approval. Drugs. 2015;75(3):329–338.
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–551.
   PubMed Web of Science ®Google Scholar
• Saeki H, Nakagawa H, Ishii T, et al. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J Eur Acad Dermatol Venereol. 2015;29(6):1148–1155.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Menter A, Gordon K, et al. AMAGINE-2: a randomized, double-blind, phase 3 efficacy and safety study of brodalumab compared with placebo and ustekinumab in moderate to severe plaque psoriasis patients [abstract]. Presented at the 73rd Annual Meeting of the American Academy of Dermatology; 2015 Mar 20; San Francisco (CA).
   Google Scholar
• Strober B, Langley RG, Blicharski T, et al. AMAGINE-3: a phase 3 study of efficacy and safety of brodalumab compared with placebo and ustekinumab in moderate to severe plaque psoriasis patients. AAD. 2015. Available from: https://www.aad.org/eposters/Submissions/getFile.aspx?id=1146&type=sub.
   Google Scholar
• Papp K, Reich K, Leonardi C, et al. Efficacy and safety of brodalumab in patients with moderate to severe plaque psoriasis: results of AMAGINE−1, a phase 3, randomized, double-blind, placebo- controlled study through week 12. AAD. 2015. Available from: https://www.aad.org/eposters/Submissions/getFile.aspx?id=275&type=sub.
   Google Scholar
• Tausend W, Downing C, Tyring S. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab. J Cutan Med Surg. 2014;18(3):156–169.
   PubMed Web of Science ®Google Scholar
• Krueger JG, Ferris LK, Menter A, et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015;136(1):116–124.e7.
   PubMed Web of Science ®Google Scholar
• Reich K, Ortonne J-P, Gottlieb AB, et al. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab’ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br J Dermatol. 2012;167(1):180–190.
   PubMed Web of Science ®Google Scholar
• Hansen RB, Kavanaugh A. Certolizumab pegol for the treatment of psoriatic arthritis. Expert Rev Clin Immunol. 2015;11(3):307–318.
   PubMed Web of Science ®Google Scholar
• Papp KA, Menter MA, Abe M, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol. 2015;173:949–961. DOI:10.1111/bjd.14018.
   PubMed Web of Science ®Google Scholar
• Bachelez H, van de Kerkhof PCM, Strohal R, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet. 2015. DOI:10.1016/S0140-6736(14)62113-9.
   Web of Science ®Google Scholar
• Koryürek ÖM, Kalkan G. A new alternative therapy in dermatology: tocilizumab. Cutan Ocul Toxicol. 2015;1–8. [Epub ahead of print].
   PubMedGoogle Scholar
• Vanderpuye-Orgle J, Zhao Y, Lu J, et al. Evaluating the economic burden of psoriasis in the United States. J Am Acad Dermatol. 2015;72(6):961–967.e5.
   PubMed Web of Science ®Google Scholar
• Package Insert. Novartis Pharmaceuticals. 2016. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/cosentyx.pdf
   Google Scholar
• Novartis Pharmaceuticals. Secukinumab in TNF-IR psoriasis patients (SIGNATURE). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine; 2000 [cited 2015 Nov]. Available from: https://clinicaltrials.gov/ct2/show/NCT01961609 NLM Identifier: NCT01961609
   Google Scholar
• Novartis Pharmaceuticals. Plaque psoriasis efficacy and safety with secukinumab (OPTIMISE). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine; 2000 [cited 2015 Nov]. Available from: https://clinicaltrials.gov/ct2/show/NCT02409667 NLM Identifier: NCT02409667
   Google Scholar
• Novartis Pharmaceuticals. Efficacy and safety of subcutaneous secukinumab in adults with moderate to severe scalp psoriasis (SCALP). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine; 2000 [cited 2015 Nov]. Available from: https://clinicaltrials.gov/ct2/show/NCT02267135 NLM Identifier: NCT02267135
   Google Scholar
• Novartis Pharmaceuticals. Pediatric study in children and adolescents with severe plaque psoriasis. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine; 2000 [cited 2015 Nov]. Available from: https://clinicaltrials.gov/ct2/show/NCT02471144 NLM Identifier: NCT02471144
   Google Scholar
• Novartis Pharmaceuticals. Extension study of secukinumab prefilled syringes in subjects with moderate to severe chronic plaque-type psoriasis completing preceding psoriasis phase III studies with secukinumab. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine; 2000 [cited 2015 Nov]. Available from: https://clinicaltrials.gov/ct2/show/NCT01544595 NLM Identifier: NCT01544595
   Google Scholar
• Novartis Pharmaceuticals. Study of Secukinumab compared to Fumaderm® in adults with moderate to severe psoriasis (PRIME). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine; 2000 [cited 2015 Nov]. Available from: https://clinicaltrials.gov/ct2/show/NCT02474082 NLM Identifier: NCT02474082
   Google Scholar
• Novartis Pharmaceuticals. Secukinumab study in PSOriasis Exploring pruRITUS intensity and lesional biomarkers (PSORITUS). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine; 2000 [cited 2015 Nov]. Available from: https://clinicaltrials.gov/ct2/show/NCT02362789 NLM Identifier: NCT02362789
   Google Scholar
• Novartis Pharmaceuticals. Secukinumab dosage optimisation in partial responders with moderate to severe plaque-type psoriasis (GAIN). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine; 2000 [cited 2015 Nov]. Available from: https://clinicaltrials.gov/ct2/show/NCT02474069 NLM Identifier: NCT02474069
   Google Scholar
• Novartis Pharmaceuticals. Palmoplantar pustular psoriasis efficacy and safety with secukinumab. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine; 2000 [cited 2015 Nov]. Available from: https://clinicaltrials.gov/ct2/show/NCT02008890 NLM Identifier: NCT02008890
   Google Scholar
• Novartis Pharmaceuticals. A 24-week, multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine; 2000 [cited 2015 Nov]. Available from: https://clinicaltrials.gov/ct2/show/NCT02394561 NLM Identifier: NCT02394561
   Google Scholar
• Novartis Pharmaceuticals. Study of safety, tolerability, and efficacy of secukinumab in subjects with moderate to severe palmoplantar psoriasis (GESTURE). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine; 2000 [cited 2015 Nov]. Available from: https://clinicaltrials.gov/ct2/show/NCT01806597 NLM Identifier: NCT01806597
   Google Scholar
• Huppler AR, Bishu S, Gaffen SL. Mucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapy. Arthritis Res Ther. 2012;14(4):217.
   PubMed Web of Science ®Google Scholar
• Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis. 2011;70(11):1895–1904.
   PubMed Web of Science ®Google Scholar
• Lis K, Kuzawińska O, Bałkowiec-Iskra E. State of the art paper. Tumor necrosis factor inhibitors – state of knowledge. Arch Med Sci. 2014;6(6):1175–1185.
   Web of Science ®Google Scholar
• Kimball AB, Guérin A, Tsaneva M, et al. Economic burden of comorbidities in patients with psoriasis is substantial. J Eur Acad Dermatol Venereol. 2011;25(2):157–163.
   PubMed Web of Science ®Google Scholar